Cargando…

A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis

Tuberculosis kills more people than any other infectious disease. Three pivotal trials testing 4-month regimens failed to meet non-inferiority margins; however, approximately four-fifths of participants were cured. Through a pooled analysis of patient-level data with external validation, we identify...

Descripción completa

Detalles Bibliográficos
Autores principales:	Imperial, Marjorie Z., Nahid, Payam, Phillips, Patrick P. J., Davies, Geraint R., Fielding, Katherine, Hanna, Debra, Hermann, David, Wallis, Robert S., Johnson, John L., Lienhardt, Christian, Savic, Rada M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group US 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6685538/ https://www.ncbi.nlm.nih.gov/pubmed/30397355 http://dx.doi.org/10.1038/s41591-018-0224-2

Ejemplares similares

Publisher Correction: A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis
por: Imperial, Marjorie Z., et al.
Publicado: (2018)

Precision-Enhancing Risk Stratification Tools for Selecting Optimal Treatment Durations in Tuberculosis Clinical Trials
por: Imperial, Marjorie Z., et al.
Publicado: (2021)

A comparison of clinical development pathways to advance tuberculosis regimen development
por: Chang, V., et al.
Publicado: (2022)

The importance of adherence in tuberculosis treatment clinical trials and its relevance in explanatory and pragmatic trials
por: Vernon, Andrew, et al.
Publicado: (2019)

Promise and Peril of Pretomanid–Rifamycin Regimens for Drug-susceptible Tuberculosis
por: Velásquez, Gustavo E., et al.
Publicado: (2023)

Treatment-shortening regimens for tuberculosis: updates and future priorities
por: Saluzzo, Francesca, et al.
Publicado: (2023)

Shortened tuberculosis treatment regimens: what is new?
por: Silva, Denise Rossato, et al.
Publicado: (2020)

Development of new TB regimens: Harmonizing trial design, product registration requirements, and public health guidance
por: Lienhardt, Christian, et al.
Publicado: (2019)

Shortened treatment regimens versus the standard regimen for drug‐sensitive pulmonary tuberculosis
por: Grace, Angeline G, et al.
Publicado: (2019)

Mycobacterium tuberculosis precursor rRNA as a measure of treatment-shortening activity of drugs and regimens
por: Walter, Nicholas D., et al.
Publicado: (2021)

Analysis of Dynamic Efficacy Endpoints of the Nix-TB Trial
por: Solans, Belén P, et al.
Publicado: (2023)

Priority-Setting for Novel Drug Regimens to Treat Tuberculosis: An Epidemiologic Model
por: Kendall, Emily A., et al.
Publicado: (2017)

A systematic review of endpoint definitions in late phase pulmonary tuberculosis therapeutic trials
por: Hills, N. K., et al.
Publicado: (2021)

Keeping phase III tuberculosis trials relevant: Adapting to a rapidly changing landscape
por: Phillips, Patrick P. J., et al.
Publicado: (2019)

Advances in clinical trial design for development of new TB treatments: A call for innovation
por: Lienhardt, Christian, et al.
Publicado: (2019)

Proposed Linezolid Dosing Strategies to Minimize Adverse Events for Treatment of Extensively Drug-Resistant Tuberculosis
por: Imperial, Marjorie Z, et al.
Publicado: (2021)

Advancing the development of new tuberculosis treatment regimens: The essential role of translational and clinical pharmacology and microbiology
por: Dooley, Kelly E., et al.
Publicado: (2019)

Analysis of Combination Drug Therapy to Develop Regimens with Shortened Duration of Treatment for Tuberculosis
por: Drusano, George L., et al.
Publicado: (2014)

Effects on the QT Interval of a Gatifloxacin-Containing Regimen versus Standard Treatment of Pulmonary Tuberculosis
por: Olliaro, Piero L., et al.
Publicado: (2017)

Predictive Modeling to Study the Treatment-Shortening Potential of Novel Tuberculosis Drug Regimens, Toward Bundling of Preclinical Data
por: Mudde, Saskia E, et al.
Publicado: (2021)

Prioritising attributes for tuberculosis preventive treatment regimens: a modelling analysis
por: Vesga, Juan F., et al.
Publicado: (2022)

Comparing the Efficacy of Drug Regimens for Pulmonary Tuberculosis: Meta-analysis of Endpoints in Early-Phase Clinical Trials
por: Bonnett, Laura J, et al.
Publicado: (2017)

Effectiveness and Pharmacokinetic Exposures of First-Line Drugs Used to Treat Drug-Susceptible Tuberculosis in Children: A Systematic Review and Meta-Analysis
por: Solans, Belén P, et al.
Publicado: (2023)

Shortening Tuberculosis treatment schedules in children
por: Barnes, Katharine
Publicado: (2022)

Is Glycemic Control the Secret to Tuberculosis Control?
por: Huddart, Sophie, et al.
Publicado: (2021)

Economic evaluation of a shortened standardised treatment regimen of antituberculosis drugs for patients with multidrug-resistant tuberculosis (STREAM): study protocol
por: Gama, Elvis, et al.
Publicado: (2016)

Model-Based Meta-Analysis of Relapsing Mouse Model Studies from the Critical Path to Tuberculosis Drug Regimens Initiative Database
por: Berg, Alexander, et al.
Publicado: (2022)

Optimizing (O) rifapentine-based (RI) regimen and shortening (EN) the treatment of drug-susceptible tuberculosis (T) (ORIENT) using an adaptive seamless design: study protocol of a multicenter randomized controlled trial
por: Feng, Zhen, et al.
Publicado: (2023)

Adherence and Associated Factors of Treatment Regimen in Drug-Susceptible Tuberculosis Patients
por: Bea, Sungho, et al.
Publicado: (2021)

Factors associated with mortality in patients with drug-susceptible pulmonary tuberculosis
por: Nahid, Payam, et al.
Publicado: (2011)

Telomeres susceptibility to environmental arsenic exposure: Shortening or lengthening?
por: Wai, Kyi Mar, et al.
Publicado: (2023)

Pharmacokinetic analysis across studies to drive knowledge‐integration: A tutorial on individual patient data meta‐analysis (IPDMA)
por: van Wijk, Rob C., et al.
Publicado: (2023)

High-Dose First-Line Treatment Regimen for Recurrent Rifampicin-Susceptible Tuberculosis
por: Decroo, Tom, et al.
Publicado: (2020)

Accelerating the transition of new tuberculosis drug combinations from Phase II to Phase III trials: New technologies and innovative designs
por: Davies, Geraint, et al.
Publicado: (2019)

Cost-effectiveness of short, oral treatment regimens for rifampicin resistant tuberculosis
por: Sweeney, Sedona, et al.
Publicado: (2022)

Scaling up target regimens for tuberculosis preventive treatment in Brazil and South Africa: An analysis of costs and cost-effectiveness
por: Nsengiyumva, Ntwali Placide, et al.
Publicado: (2022)

Modeling Treatment of Latent Tuberculosis: Shortening the Leap of Faith?
por: Vernon, Andrew, et al.
Publicado: (2020)

Targeting the Mycobacterium tuberculosis Stringent Response as a Strategy for Shortening Tuberculosis Treatment
por: Danchik, Carina, et al.
Publicado: (2021)

Multiplet shortening in Osp(N,4)
por: Freedman, Daniel Z, et al.
Publicado: (1984)

Initial steroid regimen in idiopathic nephrotic syndrome can be shortened based on duration to first remission
por: Baek, Hee Sun, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_iqqkvlvkmv2gngsk6fruqch8e1